Trials / Unknown
UnknownNCT04180982
A Safety and Efficacy Study of SHR4640 and Febuxostat in Subjects With Hyperuricemia
A Phase II, MultiCenter, Double-Blind Study to Evaluate the Efficacy and Safety of SHR4640 and Febuxostat in Subjects With Hyperuricemia
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 84 (estimated)
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The objective of the study is to assess the Safety and Efficacy of SHR4640 and Febuxostat in patients with Hyperuricemia.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SHR4640 dose1 plus Febuxostat dose1 | Tablet,dose1,QD |
| DRUG | SHR4640 dose1 plus Febuxostat dose2 | Tablet,dose1, dose2 QD |
| DRUG | SHR4640 dose2 plus Febuxostat dose3 | Tablet,dose2, dose3 QD |
Timeline
- Start date
- 2019-12-03
- Primary completion
- 2020-07-30
- Completion
- 2020-08-30
- First posted
- 2019-11-29
- Last updated
- 2019-12-02
Source: ClinicalTrials.gov record NCT04180982. Inclusion in this directory is not an endorsement.